Loading...

SGMO SANGAMO THERAPEUTICS INC Other Situations 8-K Filing

SNGM

SGM

SANGAMO THERAPEUTICS INC

(SGMO)

2023 8-K

Financial Results Announce

Stock Offering Announcement

Sangamo's Clinical Data

Management Changes

Financial Results Announced

Compliance Extension Granted

Management Changes

Management Change

Clinical Data Update

Financial Statements

Product Expansion

Equity Offerings

Equity Offerings

Delisting due to Non-Compli...

Financial Results

Clinical Data Update

Collaboration Termination

Stock Increase Validated

Financial Results

Share Increase Approval

Financial Results Announcement

Announcement of Positive Re...

Amendment and Restatement o...

Financial Results Announcement

Securities Purchase Agreement

Financial Results Announcement

Clinical Data Announcement

Departure of Directors and ...

Data Presentation

Gene Therapy Presentation

Earnings Reports

Financial Results Announcement

Amendment and Restatement A...

Financial Results and Restr...

Termination of Collaboratio...

Transfer of Deposits

FDIC Press Release

Amendment to Sales Agreement

Public Offering Decision

Financial Results Announcement

External Links:

Sangamo Therapeutics terminated Collaboration and License Agreements with Novartis and Biogen for gene regulation therapies, leading to the loss of milestone payments and royalties.

AI Assistant

SANGAMO THERAPEUTICS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.